A Phase I Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04802540 After Multiple Oral Dose Administration To Healthy Adult Volunteers.
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2010
At a glance
- Drugs TS 032 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 24 Mar 2010 Actual patient number (40) added as reported by ClinicalTrials.gov.
- 24 Mar 2010 Planned end date changed from 1 Dec 2008 to 1 Jan 2009 as reported by ClinicalTrials.gov.
- 16 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.